Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
21 Janeiro 2022 - 10:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that COVID-19
RT-PCR testing volume has increased in 2022 with the emergence of
the Omicron variant. Biocept continues to serve the community with
high-quality testing, having received more than 40,000 samples for
COVID-19 testing since the beginning of 2022 and more than 765,000
samples since initiating this service in June 2020.
“RT-PCR COVID-19 testing, like the testing we offer, is highly
sensitive and more accurate than a rapid antigen test,” said
Michael Dugan, MD, Biocept’s Chief Medical Officer and Medical
Director. “A person with suspected COVID-19 has a much better
chance of having a positive RT-PCR test than the same patient using
the antigen test. We actually test for three gene targets of
COVID-19, so we are not reliant on just one target gene or protein
as used in some other tests. Omicron variant cases notably lose the
‘S gene’ target and can easily be missed by a single gene PCR test
or single protein rapid antigen. Most positive cases we are seeing
right now have only two of the original three gene targets. These
cases can be easily missed with single target tests.”
“Demand for our COVID-19 testing service surged with the
emergence of the highly contagious Omicron variant, with most of
that demand coming from our skilled nursing facility customers,”
said Michael Nall, Biocept’s President and CEO. “We have ample
laboratory capacity to perform COVID-19 testing at these higher
levels and are working to add staff, as needed. The initial surge
in demand from our California community college customers has
subsided as many colleges are now requiring most students and staff
to be fully vaccinated and are not currently mandating PCR testing
for vaccinated individuals. That said, I’m pleased to announce a
renewal of our contract with the Foundation for California
Community Colleges, which now extends through the end of 2022.
“We are committed to providing COVID-19 RT-PCR testing services
to support our community for as long as necessary, while we
continue making investments in our oncology business,” he added.
“At this time, we cannot predict how long we will see higher
volumes for COVID-19 testing or what we might expect as the year
progresses.”
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although Biocept believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, Biocept can
give no assurance that such expectations and assumptions will prove
to have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "could,"
"expect," or "believe" or the negative of these words or other
variations on these words or comparable terminology. To the extent
that statements in this release are not strictly historical,
including without limitation statements regarding the capabilities
and potential benefits of Biocept’s CNSide assay and the ability of
Biocept’s assays to provide physicians with clinically actional
information, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risks and uncertainties,
including the risk that Biocept’s products and services may not
perform as expected. These and other risks are described in greater
detail under the "Risk Factors" heading of Biocept’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2021, filed
with the Securities and Exchange Commission (SEC) on November 15,
2021. The effects of such risks and uncertainties could cause
Biocept’s actual results to differ materially from the
forward-looking statements contained in this release. Biocept does
not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in
this press release except as required by law. Readers are advised
to review Biocept’s filings with the SEC, which can be accessed
over the Internet at the SEC's website located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220121005098/en/
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024